INO Inovio: Earnings growth forecast for next year

Inovio Pharmaceuticals (INO) management is restoring confidence through a focus on DNA medicine and pipeline transparency. The earnings per share forecast for the coming year reflects market expectations, with the figure holding at 80.40. Diversification via the drug delivery platform mitigates risks, although high pre-commercial R&D expenditures are temporarily limiting the business's overall margins.

Inovio Pharmaceuticals Inc (INO): Projected earnings per share growth rate for next year from 07/04/2022 to 11/15/2026

Comprehensive metric breakdowns and analytics for Inovio (INO)

- price and consensus price forecast:

Price Chart inovio.com|INO - Analyst Median Target

- company stock capitalization data:

Market Capitalization Inovio Pharma|INO - Company Buyout Price

- book capitalization indicators:

Net Assets per Single Share Inovio|INO - Accounting Capitalization|Market Value to Book Value Ratio inovio.com|INO - Company Assets

- debt and liquidity data:

- net income and valuation ratios data:

INO - Profit After Tax|Projected Future Earnings Inovio Pharmaceuticals|INO - Company Value to Net Income|Forward P/E Multiple inovio.com|INO - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Inovio Pharmaceuticals Inc|INO - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months Inovio|INO - Net earnings per share for the last 12 months|Quarterly EPS earnings growth inovio.com|INO - Earnings growth in current year|Earnings growth forecast for next year Inovio Pharmaceuticals

- issuer revenue and sales details:

INO - Company Sales|Projected Sales Volume Inovio Pharmaceuticals, Inc.|INO - Price to Sales|Forward Price-to-Revenue Multiple Inovio Pharmaceuticals|INO - Sales Growth YoY (TTM)

Initial company analysis:INO, Inovio Pharmaceuticals, Inc.

Assessing the operational resilience of the asset requires an analysis of future cash flows. For Inovio Pharmaceuticals (INO), key drivers include defense grants and patient retention in clinical trials, despite FDA regulatory barriers. The trend in market expectations for EPS growth reflects the discounting of profits, accounting for the impact of Fed rates on future margins. The stability of this indicator confirms the business's ability to generate income amid tight monetary policy.

Competitors of Inovio Pharmaceuticals